Oliver Witzke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2883098/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. Journal of Clinical Virology, 2020, 128, 104437.	3.1	307
2	Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2018, 29, 1979-1991.	6.1	193
3	COVID-19 immune signatures reveal stable antiviral TÂcell function despite declining humoral responses. Immunity, 2021, 54, 340-354.e6.	14.3	177
4	Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients. Cell Reports Medicine, 2020, 1, 100092.	6.5	148
5	Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: 1-Year Results of a Randomized Clinical Trial. Transplantation, 2012, 93, 61-68.	1.0	138
6	New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney International, 2011, 79, 599-612.	5.2	131
7	Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech). Viruses, 2021, 13, 756.	3.3	130
8	Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation. New England Journal of Medicine, 2019, 381, 1136-1147.	27.0	108
9	Impaired Cytotoxic CD8 ⁺ T Cell Response in Elderly COVID-19 Patients. MBio, 2020, 11, .	4.1	108
10	After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney International, 2020, 98, 1044-1052.	5.2	103
11	Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. American Journal of Transplantation, 2019, 19, 3018-3034.	4.7	97
12	Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. Clinical Infectious Diseases, 2022, 75, 690-701.	5.8	97
13	Learned immunosuppressive placebo responses in renal transplant patients. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4223-4227.	7.1	74
14	Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis. Vaccines, 2021, 9, 360.	4.4	74
15	An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in deÂnovo kidney transplant patients. Kidney International, 2019, 96, 231-244.	5.2	69
16	Th17 cells in renal inflammation and autoimmunity. Autoimmunity Reviews, 2019, 18, 129-136.	5.8	64
17	von Willebrand Factor Multimer Formation Contributes to Immunothrombosis in Coronavirus Disease 2019. Critical Care Medicine, 2021, 49, e512-e520.	0.9	56
18	Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients. Transplantation, 2018, 102, 876-882.	1.0	53

#	Article	IF	CITATIONS
19	A Pro-Inflammatory Gut Microbiome Characterizes SARS-CoV-2 Infected Patients and a Reduction in the Connectivity of an Anti-Inflammatory Bacterial Network Associates With Severe COVID-19. Frontiers in Cellular and Infection Microbiology, 2021, 11, 747816.	3.9	51
20	Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation. American Journal of Transplantation, 2018, 18, 1726-1734.	4.7	47
21	Renal Transplant Recipients Treated with Calcineurin-Inhibitors Lack Circulating Immature Transitional CD19+CD24hiCD38hi Regulatory B-Lymphocytes. PLoS ONE, 2016, 11, e0153170.	2.5	46
22	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Human Molecular Genetics, 2022, 31, 3945-3966.	2.9	46
23	Catechol-O-Methyltransferase Val158Met Polymorphism Is Associated with Somatosensory Amplification and Nocebo Responses. PLoS ONE, 2014, 9, e107665.	2.5	43
24	Evaluation of hemostasis in patients with end-stage renal disease. PLoS ONE, 2019, 14, e0212237.	2.5	43
25	Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients. Transplantation, 2017, 101, 980-986.	1.0	42
26	Effects of acute systemic inflammation on the interplay between sad mood and affective cognition. Translational Psychiatry, 2017, 7, 1281.	4.8	38
27	T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients. Journal of Clinical Virology, 2018, 105, 91-96.	3.1	35
28	COVID-19-Induced ARDS Is Associated with Decreased Frequency of Activated Memory/Effector T Cells Expressing CD11a++. Molecular Therapy, 2020, 28, 2691-2702.	8.2	35
29	Resilience and quality of life in 161 living kidney donors before nephrectomy and in the aftermath of donation: a naturalistic single center study. BMC Nephrology, 2015, 16, 164.	1.8	34
30	Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial. Nephrology Dialysis Transplantation, 2017, 32, 1060-1070.	0.7	31
31	The Magnitude and Functionality of SARS-CoV-2 Reactive Cellular and Humoral Immunity in Transplant Population Is Similar to the General Population Despite Immunosuppression. Transplantation, 2021, 105, 2156-2164.	1.0	31
32	Antiviral Active Compounds Derived from Natural Sources against Herpes Simplex Viruses. Viruses, 2021, 13, 1386.	3.3	29
33	Successful early sofosbuvirâ€based antiviral treatment after transplantation of kidneys from HCVâ€viremic donors into HCVâ€negative recipients. Transplant Infectious Disease, 2019, 21, e13146.	1.7	26
34	Observational cohort study of neurological involvement among patients with SARS-CoV-2 infection. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199370.	3.5	26
35	Prediction of renal function upon reperfusion by <i>ex situ</i> controlled oxygenated rewarming. European Journal of Clinical Investigation, 2016, 46, 1024-1030.	3.4	25
36	Increased resistance of gram-negative urinary pathogens after kidney transplantation. BMC Nephrology, 2017, 18, 164.	1.8	25

#	Article	IF	CITATIONS
37	BTLA Expression on Th1, Th2 and Th17 Effector T-Cells of Patients with Systemic Lupus Erythematosus Is Associated with Active Disease. International Journal of Molecular Sciences, 2019, 20, 4505.	4.1	24
38	Pro-Inflammatory Th1 and Th17 Cells Are Suppressed During Human Experimental Endotoxemia Whereas Anti-Inflammatory IL-10 Producing T-Cells Are Unaffected. Frontiers in Immunology, 2018, 9, 1133.	4.8	22
39	Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination. Frontiers in Immunology, 2022, 13, 816220.	4.8	22
40	Everolimus immunosuppression in kidney transplantation: What is the optimal strategy?. Transplantation Reviews, 2016, 30, 3-12.	2.9	21
41	Granzyme B producing B-cells in renal transplant patients. Clinical Immunology, 2017, 184, 48-53.	3.2	20
42	Citrate shows protective effects on cardiovascular and renal function in ischemia-induced acute kidney injury. BMC Nephrology, 2017, 18, 130.	1.8	20
43	Transplantation of Renal Allografts From Organ Donors Reactive for HCV Antibodies to HCV-Negative Recipients: Safety and Clinical Outcome. Kidney International Reports, 2017, 2, 53-59.	0.8	20
44	Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients. Vaccine, 2020, 38, 3339-3350.	3.8	20
45	Association of high HLA-E expression during acute cellular rejection and numbers of HLA class I leader peptide mismatches with reduced renal allograft survival. Immunobiology, 2017, 222, 536-543.	1.9	18
46	Susceptibility of HLA-E*01:03 Allele Carriers to Develop Cytomegalovirus Replication After Living-Donor Kidney Transplantation. Journal of Infectious Diseases, 2018, 217, 1918-1922.	4.0	18
47	Impact of lowâ€level <scp>BK</scp> polyomavirus viremia on intermediateâ€term renal allograft function. Transplant Infectious Disease, 2018, 20, e12817.	1.7	17
48	Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab. Nephrology Dialysis Transplantation, 2018, 35, 298-303.	0.7	17
49	Recipient HLA-G +3142 CC Genotype and Concentrations of Soluble HLA-G Impact on Occurrence of CMV Infection after Living-Donor Kidney Transplantation. International Journal of Molecular Sciences, 2017, 18, 2338.	4.1	16
50	Assessing SARS-CoV-2 RNA levels and lymphocyte/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity. Medical Microbiology and Immunology, 2020, 209, 657-668.	4.8	16
51	SARS-CoV-2–reactive cellular and humoral immunity in hemodialysis population. Kidney International, 2021, 99, 1489-1490.	5.2	16
52	Abnormal Expression Pattern of the IL-2 Receptor <i>î²</i> -Chain on CD4 ^{+} T Cells in ANCA-Associated Vasculitis. Disease Markers, 2014, 2014, 1-9.	1.3	15
53	Neurobehavioral consequences of small molecule-drug immunosuppression. Neuropharmacology, 2015, 96, 83-93.	4.1	15
54	IL-21 dependent Granzyme B production of B-cells is decreased in patients with lupus nephritis. Clinical Immunology, 2018, 188, 45-51.	3.2	15

#	Article	IF	CITATIONS
55	Correspondence on â€~SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'. Annals of the Rheumatic Diseases, 2021, 80, e162-e162.	0.9	15
56	HLA-E Polymorphism Determines Susceptibility to BK Virus Nephropathy after Living-Donor Kidney Transplant. Cells, 2019, 8, 847.	4.1	14
57	Evidence of cell-mediated immune response in kidney transplants with a negative mRNA vaccine antibody response. Kidney International, 2021, 100, 479-480.	5.2	14
58	IFN-γ licenses CD11b+ cells to induce progression of systemic lupus erythematosus. Journal of Autoimmunity, 2015, 62, 11-21.	6.5	12
59	Impact of immune suppressive agents on the BK-Polyomavirus non coding control region. Antiviral Research, 2018, 159, 68-76.	4.1	12
60	B-cell dynamics during experimental endotoxemia in humans. Bioscience Reports, 2019, 39, .	2.4	12
61	Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy. American Journal of Transplantation, 2018, 18, 2965-2976.	4.7	11
62	Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis. BMC Nephrology, 2019, 20, 430.	1.8	11
63	SARS-CoV-2 Seroprevalence in Healthcare Workers in Germany: A Follow-Up Study. International Journal of Environmental Research and Public Health, 2021, 18, 4540.	2.6	11
64	COVID-19 in Elderly, Immunocompromised or Diabetic Patients—From Immune Monitoring to Clinical Management in the Hospital. Viruses, 2022, 14, 746.	3.3	11
65	Phosphorylcholine antibodies are diminished in <scp>ANCA</scp> â€associated vasculitis. European Journal of Clinical Investigation, 2015, 45, 686-691.	3.4	10
66	Pretransplant serum BAFF levels are associated with pretransplant HLA immunization and renal allograft survival. Transplant Immunology, 2018, 47, 10-17.	1.2	10
67	Undue Elevation of Procalcitonin in Pediatric Paracetamol Intoxication is Not Explained by Liver Cell Injury Alone. Annals of Hepatology, 2018, 17, 631-637.	1.5	10
68	The Co-inhibitor BTLA Is Functional in ANCA-Associated Vasculitis and Suppresses Th17 Cells. Frontiers in Immunology, 2019, 10, 2843.	4.8	10
69	HLA-G 3′ untranslated region gene variants are promising prognostic factors for BK polyomavirus replication and acute rejection after living-donor kidney transplant. Human Immunology, 2020, 81, 141-146.	2.4	10
70	Characterization of injury in isolated rat proximal tubules during cold incubation and rewarming. PLoS ONE, 2017, 12, e0180553.	2.5	10
71	Optimization of sepsis therapy based on patient-specific digital precision diagnostics using next generation sequencing (DigiSep-Trial)—study protocol for a randomized, controlled, interventional, open-label, multicenter trial. Trials, 2021, 22, 714.	1.6	10
72	Sex-Specific Differences in HLA Antibodies after Pneumococcal Vaccination in Kidney Transplant Recipients. Vaccines, 2019, 7, 84.	4.4	9

#	Article	IF	CITATIONS
73	Long-Term SARS-CoV-2 Specific Immunity Is Affected by the Severity of Initial COVID-19 and Patient Age. Journal of Clinical Medicine, 2021, 10, 4606.	2.4	9
74	The Fungal Gut Microbiome Exhibits Reduced Diversity and Increased Relative Abundance of Ascomycota in Severe COVID-19 Illness and Distinct Interconnected Communities in SARS-CoV-2 Positive Patients. Frontiers in Cellular and Infection Microbiology, 2022, 12, 848650.	3.9	9
75	Are Adverse Events Induced by the Acute Administration of Calcineurin Inhibitor Cyclosporine A Behaviorally Conditioned in Healthy Male Volunteers?. Clinical Therapeutics, 2018, 40, 1868-1877.	2.5	8
76	Prevalence of active hepatitis E virus infection and efficacy of ribavirin treatment in renal allograft recipients. Transplant Infectious Disease, 2019, 21, e13088.	1.7	8
77	The detection of BKPyV genotypes II and IV after renal transplantation as a simple tool for risk assessment for PyVAN and transplant outcome already at early stages of BKPyV reactivation. Journal of Clinical Virology, 2019, 113, 14-19.	3.1	8
78	Morbidity and Mortality Rounds in Liver Transplantation. Visceral Medicine, 2016, 32, 272-277.	1.3	7
79	The Donor Major Histocompatibility Complex Class I Chain-Related Molecule A Allele rs2596538 G Predicts Cytomegalovirus Viremia in Kidney Transplant Recipients. Frontiers in Immunology, 2018, 9, 917.	4.8	7
80	Assessment of Suspected Malignancy or Infection in Immunocompromised Patients After Solid Organ Transplantation by [18F]FDG PET/CT and [18F]FDG PET/MRI. Nuclear Medicine and Molecular Imaging, 2020, 54, 183-191.	1.0	7
81	Detection of SARSâ€CoVâ€2â€specific memory B cells to delineate longâ€term COVIDâ€19 immunity. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2595-2599.	5.7	7
82	Orbital aspergillosis: a case report and review of the literature. BMC Ophthalmology, 2021, 21, 22.	1.4	7
83	Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizer–BioNTech) in Patients on Hemodialysis. Vaccines, 2022, 10, 327.	4.4	7
84	Short-term treatment with the calcineurin inhibitor cyclosporine A decreases HPA axis activity and plasma noradrenaline levels in healthy male volunteers. Pharmacology Biochemistry and Behavior, 2014, 126, 73-76.	2.9	6
85	IL-22 production of effector CD4+ T-cells is altered in SLE patients. European Journal of Medical Research, 2019, 24, 24.	2.2	6
86	Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function. Transplantation Direct, 2019, 5, e419.	1.6	6
87	Herpes Simplex Virus Type 2 Is More Difficult to Neutralize by Antibodies Than Herpes Simplex Virus Type 1. Vaccines, 2020, 8, 478.	4.4	6
88	Anti-SARS-CoV-2 T-cell Responses After mRNA Vaccination in Belatacept-treated Renal Transplant Patients. Transplantation, 2021, 105, e99-e99.	1.0	6
89	Detection of pre-existing SARS-CoV-2-reactive T cells in unexposed renal transplant patients. Journal of Nephrology, 2021, 34, 1025-1037.	2.0	6
90	Comment on SchÃfer et al. "Impact of COVID-19 on Public Mental Health and the Buffering Effect of a Sense of Coherence― High Level of COVID-19-Related Posttraumatic Stress in COVID-19 Survivors with Low Sense of Coherence. Psychotherapy and Psychosomatics, 2022, 91, 139-141.	8.8	6

#	Article	IF	CITATIONS
91	Enhancement of Cytomegalovirus-Specific Cytokine Production after Modulation of the Costimulation in Kidney Transplant Patients. Journal of Immunology Research, 2019, 2019, 1-8.	2.2	5
92	Characterization of follicular T helper cells and donor-specific T helper cells in renal transplant patients with de novo donor-specific HLA-antibodies. Clinical Immunology, 2021, 226, 108698.	3.2	5
93	The role of soluble mediators in the clinical course of EBV infection and B cell homeostasis after kidney transplantation. Scientific Reports, 2020, 10, 19594.	3.3	4
94	Generation of HBsAgâ€reactive T―and Bâ€cells following HBV vaccination in serological nonâ€responders under hemodialysis treatment. European Journal of Immunology, 2021, 51, 1278-1281.	2.9	4
95	Low efficacy of vaccination against serogroup B meningococci in patients with atypical hemolytic uremic syndrome. Bioscience Reports, 2020, 40, .	2.4	4
96	Chloroquine Suppresses Effector B-Cell Functions and Has Differential Impact on Regulatory B-Cell Subsets. Frontiers in Immunology, 2022, 13, 818704.	4.8	4
97	Effect of HLA-G5 Immune Checkpoint Molecule on the Expression of ILT-2, CD27, and CD38 in Splenic B cells. Journal of Immunology Research, 2022, 2022, 1-8.	2.2	4
98	Rituximab and B-Cell Return in ANCA-Associated Vasculitis. American Journal of Kidney Diseases, 2014, 63, 1066.	1.9	3
99	Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study. BMC Nephrology, 2018, 19, 154.	1.8	3
100	Th17 cells: do regulatory B-cells (Breg) take control in ANCA-vasculitis?. Rheumatology, 2019, 58, 1329-1330.	1.9	3
101	Randomized, open-label, comparative phase IV study on the bioavailability of Ciclosporin Pro (Teva) versus Sandimmun® Optoral (Novartis) under fasting versus fed conditions in patients with stable renal transplants. BMC Nephrology, 2019, 20, 167.	1.8	3
102	Doseâ€Dependent Acute Effects of Everolimus Administration on Immunological, Neuroendocrine and Psychological Parameters in Healthy Men. Clinical and Translational Science, 2020, 13, 1251-1259.	3.1	3
103	Severe Acute Respiratory Syndrome Coronavirus 2 Cross-Reactive B and T Cell Responses in Kidney Transplant Patients. Transplantation Proceedings, 2022, 54, 1455-1464.	0.6	3
104	Cytomegalovirus infection and rehospitalization rates after allogeneic hematopoietic stem cell and solid organ transplantation: a retrospective cohort study using German claims data. Infection, 2022, 50, 1543-1555.	4.7	3
105	Reactivations of Latent Viral Infections Are Associated with an Increased Thr389 p70S6k Phosphorylation in Peripheral Lymphocytes of Renal Transplant Recipients. Viruses, 2021, 13, 424.	3.3	2
106	Conversion to sirolimus of patients with chronic allograft nephropathy—a retrospective analysis of outcome and influencing factors. Langenbeck's Archives of Surgery, 2009, 394, 1073-1078.	1.9	1
107	Expression pattern of co-inhibitory molecules on CMV-specific T-cells in lung transplant patients. Clinical Immunology, 2019, 208, 108258.	3.2	1
108	P95â€Costimulatory molecules on CMV-specific T-cells in CMV IgG+ patients with systemic lupus erythematosus. , 2020, , .		1

#	Article	IF	CITATIONS
109	Successful Treatment of Atypical Hemolytic Uremic Syndrome with the Complement Inhibitor Eculizumab Blood, 2008, 112, 2294-2294.	1.4	1
110	Measurement of BK-polyomavirus Non-Coding Control Region Driven Transcriptional Activity Via Flow Cytometry. Journal of Visualized Experiments, 2019, , .	0.3	0
111	PO419AUTOANTIGEN-SPECIFIC TH17 AND TH22 INFLAME THE KIDNEY IN ANCA-VASCULITIS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
112	P1617RENAL TRANSPLANT PATIENTS HARBOR NEUTROPHILS SECRETING B-CELL ACTIVATING FACTOR (BAFF) WHICH CAN BE SUPPRESSED BY MTOR INHIBITORS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
113	Coronavirus Disease 2019 Associated Risk Score, Behavior, and Symptom Prevalence in German Transplant Recipients. Transplantation Proceedings, 2021, 53, 1245-1248.	0.6	0
114	MO247: Exogen ATP has a Suppressive Effect on CD4+-T-Cells In Aav-Patients And Healthy Controls. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0